Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.38 |
| ▸ | CDA | P32320 | 2/20 | 0.38 |
| ▸ | PNP | P00491 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631570 | 0.90 | PYGL (0.44) | PYGLCDAPNPMAPTPAX8 | |
| SCHEMBL16631523 | 0.86 | PYGL (0.37) | PYGLCDAPNPMAPTSLC5A2 | |
| SCHEMBL16631154 | 0.84 | PYGL (0.36) | PYGLCDAPNPMAPTPAX8 | |
| SCHEMBL16631377 | 0.83 | PNP (0.36) | PYGLCDAPNPMAPTPAX8 | |
| SCHEMBL16631425 | 0.82 | TSHR (0.33) | MAPTLMNAPMP22SMN1; SMN2 | |
| SCHEMBL18079910 | 0.81 | PYGL (0.34) | PYGLCDAPNPMAPT | |
| SCHEMBL16631525 | 0.79 | SLC28A1 (0.41) | PYGLCDAPNPSLC5A2 | |
| SCHEMBL16631579 | 0.79 | SLC5A2 (0.37) | CDAPNPSLC5A2 | |
| SCHEMBL18079948 | 0.78 | P2RX3 (0.47) | — | |
| SCHEMBL16631245 | 0.77 | PYGL (0.38) | PYGLCDAPNPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | PYGL 649/4885CDA 200/4885PNP 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.